CRISPR Therapeutics AG (NASDAQ:CRSP) JMP Securities Life Sciences Conference May 15, 2023 11:30 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Silvan Türkcan - JMP Securities Silvan Türkcan Thanks. Welcome back. My name is Silvan Türkcan, a senior analyst for JMP Securities. I cover precision medicines. It’s my pleasure to host Sam Kulkarni, CEO of CRISPR Therapeutics. Thanks for joining us today. Sam Kulkarni Thank you, Silvan, for having us. Question-and-Answer Session Q - Silv ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Bank of America Securities 2023 Health Care Conference May 9, 2023 1:40 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the morning session of the BofA Healthcare Conference. I'm Geoff Meacham. I'm the senior biopharma analyst here at BofA. And we're thrilled to have CRISPR Therapeutics here. And speaking on behalf, we have Sam Kulkarni. Sam, welcome. Sam Kulkarni Thank you. Question-and- ...

S S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other juris ...

Jon Terrett Session Type: Drug Development Special Track Session Session Title: New Drugs on the Horizon: Part 1 Employee of: CRISPR Therapeutics Stockholder in: CRISPR Therapeutics CRISPR THERAPEUTICS® standard character mark and design logo, CTX001™, CTX110®, CTX112™, CTX121™, CTX130™, CTX131™, CTX310™, CTX320™, CTX330™, COBALT™, VCTX210™, VCTX211™ and VCTX212™ are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property oftheir respec ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 10:30 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good morning, everyone. Tyler Van Buren here senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen’s 43rd Annual Healthcare Conference. For next session, it’s a privilege to have CRISPR here and in particular, Sam Kulkarni, the CEO. Sam, thank you very ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi’s 2023 Virtual Oncology Leadership Summit Conference February 22, 2023 1:00 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz - Citi Yigal Nochomovitz All right. Great. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. This is the second day of our Virtual Oncology Leadership Summit. So it's my pleasure to introduce the CEO of CRISPR Therapeutics, Sam Kulkarni. Sam, welcome. Thank you so mu ...

Item 11. Executive Compensation. The information required by this item is incorporated by reference to our Proxy Statement for our 2023 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2022. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. The information required by this item is incorporated by reference to our Proxy Statement for our 2023 Annual Meeting of Stockholders ...

CRISPR Therapeutics AG (NASDAQ:CRSP) SVB Securities Global Biopharma Conference Call February 15, 2023 1:40 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Mani Foroohar - SVB Securities Mani Foroohar Good afternoon and good morning to those still on the West Coast. Welcome to this next session of our Annual Global Biopharma Conference here at SVB Securities. I am Mani Foroohar, senior analyst, exec medicines team. And I am very fortunate to be hosting Sam Kulk ...

© 2022 CRISPR Therapeutics 1 Creating transformative gene-based medicines for serious diseases Corporate Overview | Q4 2022 Forward-Looking Statements The presentation and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics' expectations about any or all of the following: (i) its plans and expectations for its preclinical studies, clinical trials ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other juris ...